These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 15468359

  • 1. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.
    Mohan N, Edwards ET, Cupps TR, Slifman N, Lee JH, Siegel JN, Braun MM.
    J Rheumatol; 2004 Oct; 31(10):1955-8. PubMed ID: 15468359
    [Abstract] [Full Text] [Related]

  • 2. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V, Pontikaki I, Gattinara M, Fantini F.
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [Abstract] [Full Text] [Related]

  • 3. Henoch-Schönlein purpura after etanercept therapy for psoriasis.
    Lee A, Kasama R, Evangelisto A, Elfenbein B, Falasca G.
    J Clin Rheumatol; 2006 Oct; 12(5):249-51. PubMed ID: 17023811
    [Abstract] [Full Text] [Related]

  • 4. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
    Malaviya AN, Kapoor S, Garg S, Rawat R, Shankar S, Nagpal S, Khanna D, Furst DE.
    J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
    [Abstract] [Full Text] [Related]

  • 5. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
    Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN, Braun MM.
    Arthritis Rheum; 2002 Oct; 46(10):2565-70. PubMed ID: 12384912
    [Abstract] [Full Text] [Related]

  • 6. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.
    Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM.
    Arthritis Rheum; 2003 Feb; 48(2):319-24. PubMed ID: 12571839
    [Abstract] [Full Text] [Related]

  • 7. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
    de Oliveira SK, de Almeida RG, Fonseca AR, Rodrigues MC, Sztajnbok F, Diniz C.
    Acta Reumatol Port; 2007 Feb; 32(2):139-50. PubMed ID: 17572652
    [Abstract] [Full Text] [Related]

  • 8. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
    De Bandt M, Sibilia J, Le Loët X, Prouzeau S, Fautrel B, Marcelli C, Boucquillard E, Siame JL, Mariette X, Club Rhumatismes et Inflammation.
    Arthritis Res Ther; 2005 Feb; 7(3):R545-51. PubMed ID: 15899041
    [Abstract] [Full Text] [Related]

  • 9. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [Abstract] [Full Text] [Related]

  • 10. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.
    Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM.
    Clin Infect Dis; 2004 Aug 01; 39(3):295-9. PubMed ID: 15306993
    [Abstract] [Full Text] [Related]

  • 11. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.
    Exarchou SA, Voulgari PV, Markatseli TE, Zioga A, Drosos AA.
    Scand J Rheumatol; 2009 Aug 01; 38(5):328-31. PubMed ID: 19579151
    [Abstract] [Full Text] [Related]

  • 12. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.
    Am J Gastroenterol; 2013 Jan 01; 108(1):99-105. PubMed ID: 23032984
    [Abstract] [Full Text] [Related]

  • 13. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?
    Ang HT, Helfgott S.
    J Rheumatol; 2003 Nov 01; 30(11):2315-8. PubMed ID: 14677170
    [Abstract] [Full Text] [Related]

  • 14. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A, Perez VL, Hammel JP, Lowder CY.
    Ophthalmology; 2006 Dec 01; 113(12):2317-23. PubMed ID: 16996615
    [Abstract] [Full Text] [Related]

  • 15. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.
    Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, Rosenbaum JT.
    Arthritis Rheum; 2001 Jun 01; 45(3):252-7. PubMed ID: 11409666
    [Abstract] [Full Text] [Related]

  • 16. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P, Vähäsalo P, Honkanen V, Lahdenne P.
    Ann Rheum Dis; 2009 Apr 01; 68(4):552-7. PubMed ID: 18467515
    [Abstract] [Full Text] [Related]

  • 17. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.
    Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM.
    Arthritis Rheum; 2002 Dec 01; 46(12):3151-8. PubMed ID: 12483718
    [Abstract] [Full Text] [Related]

  • 18. Treating leukocytoclastic vasculitis associated with etanercept therapy. Is it necessary to stop etanercept?
    Juan A, Ribas B, Nadal C, Ros I.
    J Rheumatol; 2005 Oct 01; 32(10):2061; author reply 2061-2. PubMed ID: 16206372
    [No Abstract] [Full Text] [Related]

  • 19. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
    Deng A, Harvey V, Sina B, Strobel D, Badros A, Junkins-Hopkins JM, Samuels A, Oghilikhan M, Gaspari A.
    Arch Dermatol; 2006 Feb 01; 142(2):198-202. PubMed ID: 16490847
    [Abstract] [Full Text] [Related]

  • 20. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].
    Wallenius M, Rødevand E, Skomsvoll JF.
    Tidsskr Nor Laegeforen; 2005 Jun 16; 125(12):1664-6. PubMed ID: 15976836
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.